Q-TWiST analysis of cyclophosphamide, epirubicin, fluorouracil versus cyclophosphamide, methotrexate, fluorouracil treatment for premenopausal women with node-positive breast cancer

PharmacoEconomics

Volumn 23, Issue 1, 2005, Pages 69-75

  Radice, Davide ^a   Redaelli, Alberto ^a,b  

^a Pharmacia Corporation   (Italy)

^b NERVIANO MEDICAL SCIENCES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; FEMALE; HEALTH STATUS; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PREMENOPAUSE; PRIORITY JOURNAL; QUALITY ADJUSTED TIME WITHOUT SYMPTOMS AND TOXICITY; SIDE EFFECT; STATISTICAL ANALYSIS; SURVIVAL TIME; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AXILLA; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE III; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; LYMPHATIC METASTASIS; METHOTREXATE; PREMENOPAUSE; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS; TIME FACTORS; TREATMENT OUTCOME;

EID: 13244249804     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200523010-00006     Document Type: Article

References (13)

1. Gelber RD, Goldhirsch A. A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer. J Clin Oncol 1986; 4: 1772-9
2. Goldhirsch A. Gelber RD, Simes RJ, et al. Costs and benefits of adjuvant therapy in breast cancer: a quality adjusted survival analysis. J Clin Oncol 1989; 7: 36-44
3. Gelber RD, Gelman RS, Goldhirsch A. A QOL oriented endpoint for comparing therapies. Biometrics 1989; 45: 781-95
4. Glasziou PP, Simes RJ, Gelber RD. Quality adjusted survival analysis. Stat Med 1990; 9: 1259-76
5. Lenderking WR, Gelber RD, Cotton DJ, et al. Evaluation of the QOL associated with zidovudine treatment in asymptomatic human immunodeficiency virus infection. N Engl J Med 1994; 330: 738-43
6. Gelber RD, Cole BF, Gelber S, et al. Comparing treatments using quality-adjusted survival: the Q-TWiST method. Am Stat 1995; 49: 161-9
7. Cole BF, Gelber RD, Kirkwood JM, et al. Quality-of-life adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an eastern cooperative oncology group study. J Clin Oncol 1996; 14: 2666-73
8. Gelber RD, Goldhirsch A, Cole BF, et al. A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of adjuvant radiation therapy and chemotherapy for respectable rectal cancer. J Natl Cancer Inst 1996; 88: 1039-45
9. Common toxicity criteria, version 2.0. Bethesda (MD): National Cancer Institute (NCI), 1998
10. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. JASA 1958; 53: 457-81
11. Mounier N, Ferme C, Flechtner H, et al. Model based methodology for analyzing incomplete QOL data and integrating them into the Q-TWiST framework. Med Decis Making 2003 Jan-Feb; 23 (1): 54-66
12. Levine MN, Bramwell VH, Pritchard KI, et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. J Clin Oncol 1998; 16 (8): 2651-8
13. Efron B. Censored data and the bootstrap. J Am Stat Assoc 1981; 76: 312-9